World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients
Portfolio Pulse from Nina Zdinjak
The ARISTOCRAT study, a world-first clinical trial using cannabis-based drug Sativex to treat aggressive brain tumors, has recruited its first patients. Developed by GW Pharmaceuticals, now part of Jazz Pharmaceuticals (NASDAQ:JAZZ), Sativex was approved by the NHS in 2019 to treat muscle spasms related to multiple sclerosis. The trial aims to determine if Sativex combined with chemotherapy can help kill glioblastoma tumor cells and extend patients' lives.
May 26, 2023 | 1:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jazz Pharmaceuticals' Sativex is being used in a world-first clinical trial to treat aggressive brain tumors. The trial aims to determine if Sativex combined with chemotherapy can help kill glioblastoma tumor cells and extend patients' lives.
The ARISTOCRAT study is a world-first clinical trial using Sativex, a cannabis-based drug developed by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, to treat aggressive brain tumors. If the trial shows positive results, it could lead to increased demand for Sativex and potentially boost Jazz Pharmaceuticals' stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100